- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02353143
Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Study Overview
Status
Intervention / Treatment
Detailed Description
This trial is designed as an open label, non randomised, dose escalation and cohort expansion, first administration to human study to be conducted in approximately 20 European sites. The study is aiming to identify the Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), to assess the pharmacokinetics and to determine the clinical activity and potential immunogenicity of MEN1112, administered as IV infusion for two 21-day cycles.
Approximately 100 male and female ≥ 18 years-old patients, with a documented diagnosis of relapsed or refractory AML (not M3 FAB subtype), will be treated in the study, which consists of two steps.
Step 1 is the dose escalation phase according to a 3+3 patients cohort design. Incremental mg/Kg doses will be tested. Briefly, MEN1112 doses are to be administered to 3 patients; if no DLT is observed in a cohort of 3 DLT evaluable patients at a given dose level, the next cohort of 3 new patients will be treated with the next higher dose. In case of DLT occurrence by one of the three patients at any dose, the cohort will be expanded to 6 DLT evaluable patients at the same dose level. If two or more patients at a given dose level exhibit DLT, the dose escalation phase will be concluded as the MTD will be identified as one dose level below the one at which ≥ 2 DLT out of 6 treated patients occur.
Step 2 is the cohort expansion phase which will include patients treated at the MTD or the maximum dose level judged to be tolerable.
In each study Step, patients will be given two induction cycles of MEN1112 followed by a four-week End of Treatment period and a Follow-up period. In Step 1 and Step 2, DLT and MTD will be assessed when MEN1112 is given as a 'one shot' infusion (first group of patients) for all doses as well as a 'ramp up' administration to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).
Along the study period, adverse events, changes in hematology/serum biochemistry parameters and bone marrow treatment response will represent the major clinical findings to be monitored on regular basis. The individual experimental clinical phase will last up to 6 months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration) encompassing approx. 40 planned visits at site, including Screening,Treatment, End of Treatment, Follow-up period and the End of Study visit.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2060
-
Bruxelles, Belgium, 1200
-
Liège, Belgium, 4000
-
Roeselare, Belgium
-
Yvoir, Belgium, 5530
-
-
-
-
-
Grenoble, France
-
Lille, France, 59037
-
Lyon, France, 69495
-
Marseille, France, 13273
-
Nantes, France, 44093
-
Paris, France
-
Pierre-Bénite, France
-
Toulouse, France, 31059
-
Villejuif, France, 94805
-
-
-
-
-
Dresden, Germany
-
Essen, Germany, 45147
-
Frankfurt, Germany, 60590
-
Munich, Germany, 81377
-
-
-
-
-
Bologna, Italy, 40126
-
Brescia, Italy, 25123
-
Milano, Italy, 20132
-
Rome, Italy, 00133
-
Torino, Italy, 10126
-
-
-
-
-
Badalona, Spain, 08916
-
Barcelona, Spain, 08035
-
Pamplona, Spain
-
Salamanca, Spain
-
Sevilla, Spain
-
Valencia, Spain, 46026
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged ≥ 18 years.
- Documented definitive diagnosis of AML (according to WHO criteria, 2008) that is relapsed/refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
- WBC count ≤ 10 x 109/L at Visit 1/Day 1; hydroxyurea is allowed to lower WBC count.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Visit1/Day 1.
- Life expectancy of at least 2 months.
- Adequate renal and hepatic laboratory assessments: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to leukemic organ involvement, Total Bilirubin ≤2.0 × ULN, Serum creatinine ≤2.0 × ULN.
- Able to give written informed consent before any study related procedure
Exclusion Criteria:
- Acute promyelocytic leukaemia (French-American-British M3 classification).
- Active central nervous system involvement.
- Haematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Screening Visit.
- Active infection requiring intravenous antibiotics.
- Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities.
- Anti-tumour therapy within 14 days of study Visit 1/Day 1, excluding hydroxyurea.
- Prior participation in an investigational study (procedure or device) within 21 days of study Visit 1/Day 1.
- Radiotherapy within 28 days prior to study Visit 1/Day 1 or scheduled along the study conduct.
- Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
- Other active malignancies. History of malignancy in the last 12 months (except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast or non-melanoma skin cancer).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MEN1112
Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
|
Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients). Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity (DLT)
Time Frame: over 3 weeks after the first dose
|
Identification of DLT defined as an adverse event occurring during the first treatment cycle, judged to be related to MEN1112 and meeting any of the following criteria:
|
over 3 weeks after the first dose
|
Maximum tolerated dose (MTD)
Time Frame: over 3 weeks after the first dose
|
Identification of MTD defined as one dose level below the Maximum Administered Dose (i.e. one dose level below the one at which ≥ 2 DLTs out of 6 treated patients occur).
|
over 3 weeks after the first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Signs and Symptoms (TESSs)
Time Frame: 6 months
|
Incidence, severity, seriousness and treatment related causality of Treatment Emergent Signs and Symptoms (TESSs)
|
6 months
|
MEN1112 Pharmacokinetic (PK) parameter Cmax
Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
Cmax is the maximum serum drug concentration.
|
Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
MEN1112 PK parameter AUC (0-t)
Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
AUC (0-t) is the area under the serum concentration-time curve from time 0 extrapolated to t time
|
Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
MEN1112 PK parameter AUC (0-∞)
Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
AUC (0-∞) is the area under the serum concentration-time curve from time 0 extrapolated to infinite time
|
Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
MEN1112 PK parameter t1/2
Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
t1/2 is the drug elimination half-life
|
Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.
|
Complete remission (CR) rate
Time Frame: 6 months
|
CR rate at any time point, where CR is defined as: bone marrow blasts <5%, absence of extramedullary disease, absolute neutrophil count >1 x 109/L and platelet count > 100 x 109/L
|
6 months
|
Best response rate
Time Frame: 6 months
|
best observed response at any time point between CR, CRi [where CRi is defined as: all criteria for CR except residual thrombocytopenia (platelets <100 x 109/L) and/or neutropenia (absolute neutrophil count <1 x 109/L)] and partial remission [(PR): all haematological criteria for CR with bone marrow blasts 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%].
|
6 months
|
Overall survival
Time Frame: 6 months
|
number of days between the first study drug administration and death from any cause
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of MEN1112
Time Frame: 64 days
|
Incidence of anti-MEN1112 auto-antibodies
|
64 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Adriano Venditti, Professor, MD, Hematology Department, "Tor Vergata" University Viale Oxford, 81 00133 Rome, Italy
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARMY-1
- 2014-002433-59 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Adult Acute Myeloid Leukemia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent... and other conditionsUnited States
-
Alison WalkerCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Approved for marketingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid LeukemiaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
University of Colorado, DenverThe Leukemia and Lymphoma SocietyCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in RemissionUnited States